Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2474

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study ; volume:13 ; number:1 ; day:24 ; month:9 ; year:2012 ; pages:1-6 ; date:12.2012
BMC musculoskeletal disorders ; 13, Heft 1 (24.9.2012), 1-6, 12.2012

Creator: van der Maas, Aatke

Contributor: van den Bemt, Bart JF
Wolbink, Gertjan
van den Hoogen, Frank HJ
van Riel, Piet LCM
den Broeder, Alfons A.
SpringerLink (Online service)

DOI: 10.1186/1471-2474-13-184

URN: urn:nbn:de:1111-2016043022295

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

van der Maas, Aatke
van den Bemt, Bart JF
Wolbink, Gertjan
van den Hoogen, Frank HJ
van Riel, Piet LCM
den Broeder, Alfons A.
SpringerLink (Online service)

Other Objects (12)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Infliximab-induced hot kidneys on bone scintigraphy

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Related objects

Reset password